BioSpace News Archive

Sensorium Therapeutics today announced its incoming Chief Executive Officer. Sensorium welcomed Alexandra (Sandra) Glucksmann, Ph.D., as CEO and President, as former CEO and Co-founder, Dick Simon, transitions to an advisory role while continuing to serve on the Board of Directors.

PreveCeutical Medical Inc. is pleased to announce that it has started preparations to accelerate completion of its preclinical dual gene therapy program using our developed and in vitro validated Smart-siRNA sequences, which when paired with our proprietary bioresponsive lipid-nanoparticulate delivery systems (US patent no. 11,566,044) effectively target the PTPN1 gene.

The Quantitative Biosciences Institute, in collaboration with the Department of Psychiatry and Behavioral Sciences, at the University of California, San Francisco, reported new breakthrough research findings in the understanding of autism spectrum disorder.

Seismic Therapeutic, Inc ., the machine learning immunology company, today announced that it has closed a $121 million Series B financing.

Philochem and Blue Earth Diagnostics Announce First Three Patients Imaged in Phase 1 Clinical Trial of 68 Ga-OncoFAP ( 68 Ga-OncoFAP-DOTAGA) for Diagnostic Imaging in Solid Tumors.

Can-Fite BioPharma Ltd. today announced that it completed the design of a Phase IIa study protocol for the treatment of patients with pancreatic cancer and plans to submit the protocol shortly to ethical committees for approval.

Precision BioSciences, Inc. today announced publication in the journal Nature Metabolism of a peer reviewed manuscript titled “Efficient elimination of MELAS-associated m.3243G mutant mitochondrial DNA by an engineered mitoARCUS nuclease.”

Advanced Bionics, a global leader in cochlear implant technology, received FDA approval and announces expansion of Marvel CI product and feature offerings to improve hearing care delivery and patient outcomes, including: This press release features multimedia.

Tiziana Life Sciences Ltd. today announces that Matthew Davis, Chief Operating Officer and Chief Medical Officer will present at the Webull LIVE! with Corporate Connect: Virtual Biotech Investment Webinar on Wednesday, December 6th at 3:00 PM ET.

Alterity Therapeutics today announced that promising new data on the effect of ATH434 in a Parkinson’s disease primate model was presented at the Future of Parkinson’s Disease Conference 2023 that took place November 30 – December 3, 2023 in Austin, TX, USA.